Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 9Leukemia, Myeloid, Acute 8Burkitt Lymphoma 8Recurrence 4Leukemia, Biphenotypic, Acute 4Myelodysplastic Syndromes 3Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Down Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Immunoproliferative Disorders 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡